Get started
Author

Yuchan Kim

Observed names: Y. Kim, Y.J. Kim
OpenAlex ID: A5108911035
Radiomics Models to Predict Tumor Response and Pneumonitis in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
2025 · Monica Yadav, Wongi Woo, et al. · Journal of Clinical Medicine · 8
PDF
P1.11-01 Cobolimab with Dostarlimab and Docetaxel in Patients with Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung
2022 · H.R. Kim, C. Gridelli, et al. · Journal of Thoracic Oncology · 8
QVT score, a radiomic biomarker of vascular complexity, enables prognostication and monitoring of NSCLC immunotherapy
2026 · Young K Chae, Vamsidhar Velcheti, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
AI-based radiomics model for predicting immune checkpoint inhibitor–related pneumonitis (CIP) in patients with advanced NSCLC: An external validation study.
2024 · Seyoung Lee, Haojia Li, et al. · Journal of Clinical Oncology · 2
PDF
Abstract 2599: Methylation-based circulating tumor DNA predicts recurrence in definitively treated non-small cell lung cancer (NSCLC)
2026 · Jisoo Lee, Eun Ji Song, et al. · Cancer Research · 1
An interpretable AI-derived radiology signature to identify patients at risk of progression on the PACIFIC regimen for unresectable non-small cell lung cancer.
2024 · Omid Haji Maghsoudi, Liam IL Young Chung, et al. · Journal of Clinical Oncology · 1
CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC).
2024 · Seyoung Lee, Amogh Hiremath, et al. · Journal of Clinical Oncology · 1
Pre-treatment CT radiomics for predicting immunotherapy response in non-small cell lung cancer(NSCLC): RECIST vs. irRECIST criteria.
2024 · Monica Yadav, Jeeyeon Lee, et al. · Journal of Clinical Oncology · 1
PDF
Abstract 912: CheckpointPx, an interpretable radiology AI tool, predicts checkpoint blockade benefit independent of PDL1 status in non-small cell lung cancers (NSCLC): A multi-institutional validation study
2024 · Amogh Hiremath, Seyoung Lee, et al. · Cancer Research · 1
1856P Pembrolizumab (pembro) plus investigational agents as first-line therapy for treatment-naive PD-L1–positive advanced non–small-cell lung cancer (NSCLC): Results from KEYMAKER-U01 substudy 01B
2025 · N. Peled, T. Csoszi, et al. · Annals of Oncology
PDF
112 Multimodal AI biomarker fusing radiology, pathology, and molecular information for immune checkpoint inhibitor (ICI) response prediction in lung adenocarcinoma (LUAD)
2024 · Haojia Li, Amogh Hiremath, et al. · Regular and Young Investigator Award Abstracts
167P Tumor-immune spatial interactions on NSCLC H&E slide images predicts immunotherapy response: Preliminary external validation
2024 · L.I-Y. Chung, H. Li, et al. · Annals of Oncology
PDF
Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC).
2024 · Monica Yadav, Jeeyeon Lee, et al. · Journal of Clinical Oncology
PDF
Abstract 7529: Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in non small cell lung cancer (NSCLC) in patients treated with immunotherapy
2024 · Monica Yadav, Jeeyeon Lee, et al. · Cancer Research
Abstract 2594: AI-powered radiomics model predicts immune checkpoint inhibitor-related pneumonitis (CIP) in advanced NSCLC patients
2024 · Seyoung Lee, Amogh Hiremath, et al. · Cancer Research
Abstract 7530: Harmonization radiomics models to predict tumor response in non-small cell lung cancer (NSCLC) patients treated with immunotherapy
2024 · Monica Yadav, Jeeyeon Lee, et al. · Cancer Research
1543 Type 1 interferon signaling correlates with patient-reported itch in dermatomyositis
2023 · Y. Kim, S. Chunduru, et al. · Journal of Investigative Dermatology
PDF
Works count: 17
Citation count: 26
H-index: 3
I10-index:
Year
Topic
Type